Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Bibliographic Details
Main Authors:	Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129499/

Similar Items

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
by: Andtbacka, Robert HI, et al.
Published: (2014)

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
by: Andtbacka, Robert H. I., et al.
Published: (2016)

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
by: Kaufman, Howard L, et al.
Published: (2014)

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
by: Harrington, Kevin J, et al.
Published: (2016)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
by: Kaufman, Howard L., et al.
Published: (2016)

Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
by: Orloff, Marlana
Published: (2016)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
by: Lillian Sun, et al.
Published: (2018-05-01)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
by: Long, Georgina V, et al.
Published: (2015)

Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
by: Puzanov, Igor, et al.
Published: (2013)

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
by: Quinn, Casey, et al.
Published: (2016)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
by: Rehman, Hasan, et al.
Published: (2016)

A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
by: Hecht, J Randolph, et al.
Published: (2015)

Intralesional therapy for advanced melanoma: promise and limitation
by: Agarwala, Sanjiv S.
Published: (2015)

High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma
by: Mohiuddin, Majid, et al.
Published: (2015)

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
by: Andtbacka, Robert HI, et al.
Published: (2015)

A deletion of FGFR2 creating a chimeric IIIb/IIIc exon in a child with Apert syndrome
by: Fenwick, Aimee L, et al.
Published: (2011)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
by: Patel, Sapna, et al.
Published: (2014)

Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients
by: Sigalotti, Luca, et al.
Published: (2012)

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma
by: Nemunaitis, John J, et al.
Published: (2014)

The cost of unresectable stage III or stage IV melanoma in Italy
by: Maio, Michele, et al.
Published: (2012)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
by: Shelledy, Lindsay, et al.
Published: (2015)

OptiSonde chilled mirror hygrometer
Published: (2008)

OptiSonde chilled mirror hygrometer
Published: (2008)

Increased number of negative lymph nodes is associated with improved cancer specific survival in pathological IIIB and IIIC rectal cancer treated with preoperative radiotherapy
by: Li, Qingguo, et al.
Published: (2014)

Prognostic value of the standardized uptake value for 18F-fluorodeoxyglucose in patients with stage IIIB melanoma
by: Bastiaannet, E., et al.
Published: (2012)

Optimized Brain Extraction for Pathological Brains (optiBET)
by: Lutkenhoff, Evan S., et al.
Published: (2014)

New clarity in adhesion from Opti-tec at Intertronics
Published: (2006)

OPTI‐NET at Hertfordshire Libraries, Arts and Information
by: Richard, Church
Published: (1995)

Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy
by: Schopper, Heather, et al.
Published: (2016)

Internet's Islamic information credibility scale (IIICS)
by: Ishak, Mohd Sobhi, et al.
Published: (2011)

Internet's Islamic Information Credibility Scale (IIICS)
by: Nur Munawwarah
Published: (2011)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
by: Thompson, John F., et al.
Published: (2014)

Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis
by: Ma, Qiufei, et al.
Published: (2016)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
by: Middleton, Mark R., et al.
Published: (2016)

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma
by: Telang, Sucheta, et al.
Published: (2011)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
by: Revicki, Dennis A, et al.
Published: (2012)

Population survival impact of new targeted and immune based therapies for metastatic or unresectable melanoma
by: Paul Nguyen, et al.
Published: (2018-08-01)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
by: Brohl, Andrew S., et al.
Published: (2016)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
by: Yamazaki, N., et al.
Published: (2015)